"Glucosides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D005960
|
| MeSH Number(s) |
D09.408.348
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Glucosides".
Below are MeSH descriptors whose meaning is more specific than "Glucosides".
This graph shows the total number of publications written about "Glucosides" by people in this website by year, and whether "Glucosides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 2 | 1 | 3 |
| 2019 | 2 | 1 | 3 |
| 2020 | 3 | 2 | 5 |
| 2021 | 3 | 3 | 6 |
| 2023 | 1 | 0 | 1 |
| 2024 | 2 | 1 | 3 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glucosides" by people in Profiles.
-
Retinal Ischemia: Therapeutic Effects and Mechanisms of Paeoniflorin. Int J Mol Sci. 2025 Nov 11; 26(22).
-
Empagliflozin Reduces Risk of Hospitalization in Patients With Chronic Kidney Disease in the EMPA-KIDNEY Trial. Clin Ther. 2025 Dec; 47(12):1091-1096.
-
Acute Hemodynamic Effects of Empagliflozin: Are They Relevant to the Clinical Practice? Cardiovasc Drugs Ther. 2024 Aug; 38(4):769-770.
-
Four weeks SGLT2 inhibition improves beta cell function and glucose tolerance without affecting muscle free fatty acid or glucose uptake in subjects with type 2 diabetes. Basic Clin Pharmacol Toxicol. 2024 May; 134(5):643-656.
-
Dapagliflozin for Atrial Fibrillation. Cardiovasc Drugs Ther. 2024 Feb; 38(1):1-3.
-
Effects of Dapagliflozin on Myocardial Gene Expression in BTBR Mice with Type 2 Diabetes. Cardiovasc Drugs Ther. 2025 Feb; 39(1):43-61.
-
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021 11; 27(11):1954-1960.
-
An in vivo and in vitro model on the protective effect of corilagin on doxorubicin-induced cardiotoxicity via regulation of apoptosis and PI3-K/AKT signaling pathways. J Biochem Mol Toxicol. 2021 Dec; 35(12):e22926.
-
Ticagrelor and Dapagliflozin Have Additive Effects in Ameliorating Diabetic Nephropathy in Mice with Type-2 Diabetes Mellitus. Cardiovasc Drugs Ther. 2022 10; 36(5):829-840.
-
Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trial. Diabetes Obes Metab. 2021 06; 23(6):1426-1430.